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Background: Creatine monohydrate has become a very popular nutritional supplement for its ergogenic effects.
The safety of creatine monohydrate has previously been confirmed. However with each novel form of creatine that
emerges, its safety must be verified. Therefore, the purpose of this study was to examine the safety of a novel form
of creatine, creatine nitrate (CN), over a 28 day period.
Methods: 58 young males and females (Pooled: 24.3 ± 3.9 years, 144.9 ± 8.0 cm, 74.2 ± 13.0 kg) participated in this
study across two laboratories. Subjects were equally and randomly assigned to consume either 1 g (n = 18) or 2 g
(n = 20) of CN or remained unsupplemented (n = 20). Blood draws for full safety panels were conducted by a
trained phlebotomist prior to and at the conclusion of the supplementation period.
Results: Pooled data from both laboratories revealed significant group x time interactions for absolute
lymphocytes and absolute monocytes (p < 0.05). Analysis of the 1 g treatment revealed lab x time
differences for red blood cell distribution width, platelets, absolute monocytes, creatinine, blood urea
nitrogen (BUN):creatinine, sodium, protein, and alanine aminotransferase (ALT) (p < 0.05). Analysis of the
2 g treatment revealed lab x time differences for BUN:creatinine and ALT (p < 0.05). BUN and BUN:creatinine
increased beyond the clinical reference range for the 2 g treatment of Lab 2, but BUN did not reach
statistical significance.
Conclusion: Overall, CN appears to be safe in both 1 g and 2 g servings daily for up to a 28 day period. While
those with previously elevated BUN levels may see additional increases resulting in post-supplementation values
slightly beyond normal physiological range, these results have minor clinical significance and are not cause for
concern. Otherwise, all hematological safety markers remained within normal range, suggesting that CN
supplementation has no adverse effects in daily doses up to 2 g over 28 days and may be an alternative to
creatine monohydrate supplementation.
Keywords: Creatine, Nitrate, Safety, Health, Hematology, Immunity, Immune systemIntroduction
In regards to ergogenic supplementation, creatine’s ef-
fects have been researched in humans since the early
1990’s. Earnest and colleagues examined supplemental
creatine’s effects on both body composition and muscu-
lar performance [1]. After supplementing with creatine
for only 2 weeks, subjects were tested with three 30s* Correspondence: jordan@musclepharm.com
2MusclePharm Sports Science Institute, MusclePharm Corp., Denver, CO, USA
4Department of Sports Exercise Science, United States Sports Academy,
Daphne, AL, USA
Full list of author information is available at the end of the article
© 2014 Joy et al.; licensee BioMed Central. Thi
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Wingate sprints, 1 repetition maximum in the bench
press, and repetitions to failure at 70% 1RM. They dis-
covered that creatine supplementation improved re-
peated sprint performance, bench press strength, fatigue
resistance, body weight, and relative lifting volume. They
also observed an insignificant trend for fat free mass.
Creatine has since been verified as a potent supplement
for each of these and more variables on numerous occa-
sions [2-5].
Creatine supplementation’s ergogenic effects are
largely explained by increasing intramuscular phospho-
creatine (PCr) stores [6]. The increase in PCr allowss is an Open Access article distributed under the terms of the Creative
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lated to adenosine triphosphate (ATP) [7,8], which is de-
pleted rapidly during strenuous exercise. Thus, increasing
the amount of PCr through creatine supplementation
increases the capacity to rephosphorylate ADP to ATP,
and this allows the athlete to resist fatigue and maintain a
higher level of performance [6,9-11].
This increase in fatigue resistance created by creatine
supplementation allows for increased training volume.
As demonstrated by several laboratories, creatine sup-
plementation is able to increase repetitions to failure
[1,12]. Therefore, many athletes have adopted creatine
use during pre-season and/or off-season training for the
cumulative effects of increased training volume [13], and
they are not using creatine exclusively for acute per-
formance benefits. In addition to chronic performance
benefits, creatine aids those seeking to increase muscle
mass [2-5,14]. Muscle mass increases can be explained
in part by creatine increasing training volume [1], but it
is also partially explained by other factors. Saremi et al.
[5] confirmed creatine’s effects on increasing lean body
mass after chronic resistance training, and in addition,
they observed decreased levels of myostatin in the creat-
ine supplemented group. Olsen and colleagues have
demonstrated increased myonuclei and muscle fiber area
after 16 weeks of concurrent resistance training and cre-
atine supplementation [15]. Additionally, 12 weeks creat-
ine supplementation has been demonstrated to increase
myogenic regulatory factor expression and myogenin,
both of which initiate transcription and regulate gene
expression, which likely contribute to the anabolic ef-
fects of creatine [16].
Similarly, dietary nitrate has been receiving more at-
tention for its effects on energy efficiency and work cap-
acity. Nitrate supplementation, typically in the form of
foods or juices high in inorganic nitrate such as beet
root juice, has primarily been demonstrated to decrease
oxygen cost despite maintaining work load [17-21]. This
has led to improved performance [22,23] and increased
muscle contractile efficiency by decreasing the ATP cost
of muscle contraction [17,24]. Despite health benefits of
nitrate supplementation [25,26], concerns have been
raised over nitrosamines [27,28], and consumers may
still be weary of consumption. It is also possible that
healthcare practitioners may not fully understand the
role of nutritional supplements, nutrition, and exer-
cise, and therefore, they may raise unfounded safety
concerns.
Because of the ergogenic effects of creatine and
phosphocreatine and the ATP sparing effects of nitrate
[17], the two supplements have been combined effica-
ciously along with other ingredients [29]. While both
nitrates and creatine should help enhance performance
similar to taking both ingredients alone, little is knownabout the safety of creatine bound to a nitrate when
ingested regularly. Therefore, the purpose of this study
was to examine the safety of a novel form of creatine,
creatine nitrate (CN). We hypothesized that CN supple-




In a randomized design, a total of 58 subjects were re-
cruited for this study across two laboratories. Subjects
were randomly divided into control (CRL), 1 serving
(G1), or 2 serving (G2) groups. Wherein, the CRL group
did not supplement and G1 and G2 consumed 1 serving
(1 g) and 2 servings (2 g) of CN (Iron Cre3™, MusclePharm
Inc., Denver, CO), respectively, every day for 28 days in an
unblinded manner. In addition to the CN, the supplement
contained 1 g of carbohydrate, 500 mg of vitamin C,
500 IU of Vitamin E, 18 mg of Calcium, and 800 mg of a
proprietary blend consisting of taurine, coconut water
powder, and L-glutamine per serving. Supplement con-
tainers were weighed prior to and following the supple-
mentation period and supplement consumption logs were
completed by each participant to ensure compliance. Blood
draws were conducted prior to and at the conclusion of
the supplementation period. MusclePharm Sports Science
Institute (Lab 1) received approval from the MusclePharm
Sports Science Institute IRB, and the University of Tampa
Human Performance and Nutrition Laboratory (Lab 2)
received approval from the University of Tampa IRB. Each
subject was provided written informed consent prior to
participation in the study.
Participants
Forty-two subjects (25.2 ± 4.9 years, 173.8 ± 10.2 cm,
77.2 ± 16.7 kg, CRL n = 20, G1 n = 10, G2 n = 12) were
recruited by Lab 1, while Lab 2 recruited the remaining
16 (21.9 ± 1.1 yrs, 68.9 ± 2.3 cm, 66.4 ± 3.2 kg, G1
n = 8, G2 n = 8). Subjects were required to be at
least recreationally active (≥ 3 days/week of moderate
to vigorous intensity exercise), free of any disease or
disorder which may produce confounding results,
non-smokers, and have abstained from creatine or nitrate
supplementation for the month immediately prior to
beginning CN supplementation, as assessed by pre-
participation health history, exercise, and supplemen-
tation questionnaires.
Measurements
All measurements were taken prior to and at the conclu-
sion of the 28-day supplementation period. Following a
10-hour fast, all subjects submitted a blood sample for
analysis in the morning to prevent diurnal variations.
All blood draws were performed via venipuncture by
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complete metabolic panels and complete blood counts
by an external laboratory (Laboratory Corporation of
America, Denver, CO; ANY LAB TEST NOW,
Tampa, FL). All collected samples were analyzed for
the following markers: white blood cell count (WBC),
red blood cell count (RBC), hemoglobin, hematocrit,
mean corpuscular volume (MCV), mean corpuscular
hemoglobin (MCH), mean corpuscular hemoglobin
concentration (MCHC), red blood cell distribution width
(RDW), platelets (percent and absolute), neutrophils
(percent and absolute), lymphocytes (percent and absolute),
monocytes (percent and absolute), eosinophils (percent and
absolute), basophils (percent and absolute), serum glucose,
blood urea nitrogen (BUN), creatinine, estimated glomeru-
lar filtration rate (eGFR), BUN:creatinine, sodium, potas-
sium, chloride, carbon dioxide, calcium, protein, albumin,
globulin, albumin:globulin, bilirubin, alkaline phosphatase,
aspartate aminotransferase (AST), and alanine aminotrans-
ferase (ALT). Intra-test Coefficient of Variation (CV) for
Lab 2 blood measurements were all under 3%. Inter-test re-
liability results from 12 men and women measures up to
one week apart from Lab 1 resulted in no significant differ-
ences from day-to-day (p > 0.05) and an average inter-test
%CV of 6.9%.Statistical analyses
Pooled data was analyzed using a 3x2 repeated measures
ANCOVA model for all group, time, and group by time
interactions with the pre value as the covariate. A bon-
ferroni post-hoc analysis was used to locate differences.
Shapiro-Wilk tests were used to determine normality of
the data. The Minimal Difference (MD) needed to be
considered real was determined using the method previ-
ously described by Weir [30]. Data are presented as
mean ± standard deviation. All data were analyzed using
Statistica software (Statsoft, 2011).Results
Pooled
Significant group by time interactions were present for
absolute lymphocytes (p < 0.05). Wherein, G1 increased to
a lesser extent than CRL, G2 decreased significantly rela-
tive to CRL, and G2 significantly decreased from pre to
post. Absolute lymphocytes had a normal distribution at
baseline (p = 0.55), yet the distribution was negatively
skewed (p < 0.05) after the supplementation period.
Significant group by time interactions were present
for absolute monocytes (p < 0.05). G1 increased rela-
tive to CRL and G2 increased to a lesser extent than
G1. Absolute monocytes was positively skewed at
both time points (p < 0.05). All data is presented in
Additional file 1: Table S1.Inter-laboratory comparisons: one serving
Significant group by time interactions were present for
RDW (p < 0.05). Lab 2 observed greater increases in
RDW relative to Lab 1 and significantly increased from
pre to post. Significant group by time interactions were
observed for platelets (p < 0.05). Lab 1 observed a signifi-
cant decrease in platelets relative to CRL, and Lab 2 ob-
served a significant increase in platelets compared to
decrements in both CRL and Lab 1. Platelets were nor-
mally distributed at baseline (p = 0.17), and negatively
skewed (p < 0.05) at post. Significant group by time in-
teractions existed for absolute monocytes (p < 0.05).
Wherein, Lab 2 observed significant increases compared
to Lab 1 and CRL. Significant group by time interactions
were present for creatinine (p < 0.05). Lab 2 observed
significant decrements relative to CRL. A significant
group by time interaction was present for BUN:creatin-
ine (p < 0.05). Wherein, Lab 2 observed significant in-
creases pre to post. A significant group by time
interaction was observed for sodium (p < 0.05). Lab 2
observed a significant increase over CRL. A significant
interaction was observed for serum protein (p <0.05).
Lab 2 observed a significant increase relative to CRL.
Significant group by time interactions were observed for
ALT (p < 0.05). Lab 2 observed greater decrements rela-
tive to CRL and Lab 1. ALT was positively skewed at
baseline (p < 0.05), but it was normally distributed (p =
0.52) at post. RDW, platelets, absolute monocytes, cre-
atinine, BUN:creatinine, sodium, and serum protein were
either normally distributed, negatively skewed, or posi-
tively skewed at baseline without a change in skewness
at post. With the exception of BUN:creatinine, all of
these markers remained within clinical reference ranges,
indicating clinical insignificance. All data is presented in
Additional file 2: Table S2.
Inter-laboratory comparisons: two serving
Significant group by time interactions were present for
BUN:creatinine (p < 0.05). Lab 2 observed significant in-
creases relative to CRL and Lab 1 as well as within
group differences pre to post. BUN:creatinine was posi-
tively skewed at baseline (p < 0.05), and at post, it be-
came normally distributed (p = 0.16). Significant group
by time interactions were observed for ALT (p < 0.05).
Wherein, Lab 1 and Lab 2 observed greater decrements
than CRL. ALT was positively skewed at baseline (p <
0.05), yet it was normally distributed at post (p = 0.93).
All data is presented in Additional file 3: Table S3.
Discussion
The results of the present study confirm our hypothesis
that CN supplementation will not cause abnormal
changes in hematological safety markers. When analyz-
ing the pooled data from both laboratories, significant
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cytes and monocytes, yet these remained within the
accepted physiological range and not clinically signifi-
cant. Also, percent lymphocytes and monocytes were
unchanged. While remaining within range, we observed
unusual effects between groups. For lymphocytes, the
CRL group had a greater change than G1, and for
monocytes, G1 increased to a greater extent than G2.
These results suggest a natural variation for these
markers. Alternatively, data was collected during the
winter months, and subjects may have experienced these
unusual outcomes as an effect of weather. Although sig-
nificant interactions were observed concerning Lab 2 in
the one serving treatment, it must be mentioned that
many of these differences were not observed in the two
serving treatment, and the CRL sample was represented
solely from Lab 1. Thus, some of the differences are not
likely due to CN supplementation, and variations
between subjects may be due to variations in climate be-
tween Denver, CO and Tampa, FL [31]. However, the
difference in absolute monocytes may have influenced
the significance observed for absolute monocytes in the
pooled sample. In the analysis of both the one and
two serving treatments, significant interactions were
observed for ALT, yet CN supplementation appeared
to lower ALT relative to control, which is not a cause
for concern. When analyzing the data between labora-
tories, BUN:creatinine from Lab 2 increased beyond
the acceptable range for the two serving treatment
(Additional file 3: Table S3). This was likely due to a
large, yet insignificant (p = 0.40), increase in BUN,
which was also slightly outside the acceptable range
after the supplementation period. However, subjects
were already at the high end of the acceptable range,
and the magnitude of change was attenuated when
examining a larger sample (Additional file 1: Table S1).
Analysis of clinical significance at the individual level
was conducted using the MD statistic that calculates the
(biological and reliability) error needed to be exceeded
in order for an individual measurement to be considered
real as described by Weir [30]. If a subject exceeded the
MD, the change was considered a true change. Variables
that were significantly different at the group level were
evaluated at the individual level and subjects with
changes that exceeded MD were evaluated to determine
clinical significance. Clinical significance at the individ-
ual level was reached when a score that exceeded the
MD crossed the upper or lower limits for each variable.
In the pooled analysis, one subject in G2 experienced a
decrease in absolute monocytes, bringing them within
the clinical reference range, and two subjects from G1
equally increased, entering the clinical reference range,
and decreased, exiting the reference range. In both cases,
the supplement does not appear to be causing specific,directional changes in absolute monocytes. In the 1 serv-
ing inter-laboratory comparison, 2 subjects from Lab 2
demonstrated increases in RDW, which caused them to
surpass the upper limit of the clinical reference range.
One subject from Lab 2 decreased, leaving the accepted
range, for creatinine. One subject from Lab 2 increased,
leaving the accepted range, for BUN:Cr. From Lab 1,
one subject experienced a decrease in ALT, entering the
accepted range. In the 2-serving comparison, 4 subjects
from Lab 2 increased; 2 started in and remained outside
the range, and 2 exited the range. All subjects remained
within 3 standard deviations of the mean and exceeded
the MD. It is also worthy to note that 8 subjects in the
CRL group experienced changes in at least one variable
that exceeded the MD and was outside the accepted
range. Collectively, individual analyses supports our
hypothesis and also supports the notion of variability.
Additionally, absolute lymphocytes in the pooled analysis,
platelets and ALT in the 1 serving inter-laboratory
analysis, and BUN:creatinine and ALT in the 2 serv-
ing inter-laboratory analysis were distributed differ-
ently from pre to post, increasing the probability for
type 1 statistical error [32].
The present findings generally agree with previous
literature. The safety of creatine has been confirmed on
several occasions [33], including several clinical popula-
tions [34,35]. Shelmadine et al. [36] examined the safety
of a multi-ingredient supplement containing creatine,
ingredients known to influence the nitrate/nitric oxide
pathway, and other ingredients over an identical time
period of 28 days. These researchers observed no change
in clinical serum or whole blood chemistry markers, and
they concluded that the supplement was safe for con-
sumption for this duration. Other multi-ingredient
supplements containing creatine have confirmed its
safety for a period of up to nine weeks [37,38].
While creatine monohydrate is recognized as safe, the
nitrate component of CN may still be troublesome to
athletes or practitioners. Concerns over nitrate and other
nitrosamines began as early as 1970. Lijinsky and Epstein
[28] published a manuscript identifying dietary nitrosa-
mines as carcinogens. However, more recent evidence
suggests that dietary nitrate is safe for human consump-
tion [39]. Moreover, dietary nitrate has been reported to
reduce blood pressure [19,21,25]. Webb et al. [40] pro-
vided subjects with beetroot juice high in nitrates and
observed lower systolic blood pressure after only one
hour, while diastolic blood pressure and mean arterial
pressure remained significantly lower after 24 hours.
These findings identify nitrate as possibly beneficial to
long-term health. In a review of nitrate supplementation,
Hoon and colleagues [41] reported no major health con-
sequences of nitrate supplementation, and only one
minor adverse event, the discoloration of urine, which is
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beet-root juice. However, provided that creatine’s safety
has been so thoroughly investigated, any health compli-
cation from CN is likely due to the nitrate component.
This is the first study to examine the safety of CN.
From the present results, we can conclude that CN in
doses of up to 2 g are safe for human consumption for a
duration of 28 days. All measured variables remained
within the normal range across groups, with the excep-
tion of BUN which was not statistically significant when
the groups were compared. Therefore, CN supplementa-
tion may be contraindicated for those already high in
BUN. Additionally while the differences observed for
absolute monocytes and lymphocytes appear to be due
to variability and remained within range, CN may be
unadvisable for daily consumption for those with a
weakened immune system. In the present study, CN was
supplemented for only 28 days, and future research may
be interested in examining CN for a longer trial period to
confirm its safety. Moreover, future studies are required to
determine the efficacy of CN, as the combined effects
of nitrates and creatine on both longitudinal and
acute changes in performance and body composition
are currently unknown.Additional files
Additional file 1: Table S1. Pooled data from Lab 1 and Lab 2. All data
are presented as mean ± standard deviation. * denotes significantly
different from CRL, a denotes significantly different from pre value, and b
denotes significantly different from G1.
Additional file 2: Table S2. Data comparison between Lab 1 and Lab 2
for the 1 serving treatment. All data are presented as mean ± standard
deviation. * denotes significantly different from CRL, a denotes
significantly different from pre value, and b denotes significantly different
from Lab 1.
Additional file 3: Table S3. Data comparison between Lab 1 and Lab 2
for the 2 serving treatment. All data are presented as mean ± standard
deviation. * denotes significantly different from CRL, a denotes
significantly different from pre value, and b denotes significantly different
from Lab 1.
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